AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

What is helping drive the increase of drug-resistant infections in Ukraine, why should the UK be on alert, and importantly, what can be done about it?

A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

“These infections are particularly troublesome ... materials that will help bones heal while also killing drug-resistant bacteria at the site of combat injuries. Prof Roberts said fighting ...

Antibiotic resistance is a global public health crisis responsible for more than a million deaths annually. By 2050, the ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Botulism is a rare bacterial infection caused by a potent neurotoxin that can be ingested accidentally when eating ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.